Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAALL-F01: French protocol for treatment of childhood and adolescent acute lymphoblastic leukemia
2024-514243-29-01Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of pegaspargase in acute lymphoblastic leukemia (ALL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Adequate asparaginase activity at day 33 of induction and Severe asparaginase-related toxicity between day 12 and day 49. Planned start Oct 2024; status: authorised.
02
Drugs
pegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-514243-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514243-29-01.